Altered secretion of adipokines and accumulation of visceral fat are contributing factors in the development of many metabolic diseases, including type 2 diabetes mellitus. Chemerin has been discovered as the most prominent new visceral Adipokine that may contribute to type 2 diabetes by enhancing insulin resistance. The aim of this study is to evaluate serum chemerin levels in obese/ non-obese patients with T2DM and investigated relationship between serum chemerin levels with waist circumference. 88 individuals were included, they were divided into 4 groups, 37 obese patients with type 2 diabetes, 33 lean patients with type 2 diabetes, 8 obese individuals and 10 lean individuals. Body Mass Index (BMI) was calculated, Waist Circumference (WC) was taken for each study participant and serum chemerin levels were measured by Enzyme-Linked Immunosorbent Assay (ELISA). The results of this study showed a statistically significant increase in serum chemerin levels in obese diabetics group (182.27±39.73 ng/ml) compared to lean diabetics group (156.81±28.23 ng/ml) (P=0.022), obese group (141.59±24.51 ng/ml) (P=0.025( and lean group (95.87±27.28 ng/ml) (P<0.0001). Also, there was a statistically significant increase in the serum chemerin levels in lean diabetic group compared to the lean group (P<0.0001). There was a statistically significant correlation between serum chemerin levels and WC values in obese diabetic group (R=0.651, P<0.0001), lean diabetic group (R=0.358, P=0.041). The current study confirms that chemerin is an adipokine secreted from visceral adipose tissue in diabetics type 2 and it indicates that chemerin is one of the proteins with altered secretion that predisposes to the development of (T2DM).